India, Jan. 30 -- February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart Month was officially declared by President Lyndon B. Johnson in 1964.
Heart disease remains the leading cause of death in the United States, and it caused 702,880 deaths in 2022, according to the latest data from the CDC.
Let's take a look at the biotech stocks awaiting FDA decisions in February.
Supernus Pharmaceuticals Inc. (SUPN)
The FDA decision on Supernus Pharma's SPN-830, an investigational apomorphine infusion device for the continuous treatment of motor fluctuations ("OFF" episodes) in Parkinson's disease, is expected on February 1, 2025.
SPN-830 is a continuous subcutaneous infus...